📈 Analyzing 3,000+ tickers daily — free strategy scores, market data, and a ticker extraction tool. No account required.

AXGN

NASDAQ Healthcare

Axogen, Inc. - Common Stock

Medical Devices

Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization. It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors. The company is headquartered in Alachua, Florida.

🎯 投资策略评分

AXGN 在各投资策略中的评分。分数越高,越符合该策略目标。

高股息率 + 低波动性
高增长潜力(高贝塔 + 超卖)
逆向投资(超卖 + 低于移动均线)
超买股票(潜在做空标的)
大盘、机构级别股票
🔍 策略解读

最佳匹配: 🚀 Moon Shot (52/100) — 此策略 高增长潜力(高贝塔 + 超卖).

评分最低的策略: 🔪 Falling Knife (11/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →

在文本中查找 AXGN in your text

粘贴任何文章、记录或帖子 — 工具将提取 AXGN 以及每一个其他隐藏的股票代码。

试试股票代码提取器 →

免责声明:本数据仅供教育和娱乐用途,不构成金融建议。市场数据可能存在延迟。在做出投资决策之前,请始终进行自己的研究。
数据最后更新: 2026-04-17.